<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>17633921</identifier>
<setSpec>0210-4806</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Carrera Vazquez, A</dc:author>
<dc:author>San Miguel Fraile, P</dc:author>
<dc:author>Barreiro Barbosa, M J</dc:author>
<dc:author>Gómez de María, C</dc:author>
<dc:author>Iglesias Martínez, P</dc:author>
<dc:author>Donis Quintairos, L</dc:author>
<dc:description xml:lang="en">OBJECTIVE We examined the presence of E-cadherin and alpha, beta and gamma catenins detected by immunohistochemistry and correlated with the classic variables: grade, stage and recurrence. MATERIAL AND METHOD The authors evaluated 37 transitional cell carcinomas. Biopsy specimens included no recurrent transitional cell carcinoma (n=19) and recurrent transitional cell carcinoma (n=18). Association of E-cadherin and alpha, beta and gamma catenins immunoreactivity with tumor grade, clinical stage and tumor recurrence was examined. RESULTS E-cadherin and gamma catenin expression were related to the clinical stage of the disease, alpha and beta catenins were not correlated with grade, stage and recurrence of disease. CONCLUSIONS Decreased E cadherin and gamma catenin expression were associated with advanced stage of the disease.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2007 Apr </dc:date>
<dc:title xml:lang="es">Expresión de cadherina E y cateninas en los carcinomas uroteliales.</dc:title>
<dc:title xml:lang="en">[Expresion of E-cadherin and catenins in urothelial carcinomas].</dc:title>
<dc:publisher>Actas urologicas espanolas</dc:publisher>
</metadata>
</record>
</pubmed-document>
